Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study

Participants will be receiving a customized bioidentical hormone regimen which may include a combination of estrogens, progesterone, and testosterone.

Inclusion criteria

• Participants must be women who are in surgically or naturally induced menopause or perimenopause, as determined by their physician.
• Participants must be starting a new regimen of bioidentical hormone replacement therapy.
• Participants must be expected to receive therapy for at least 12 weeks.
• Participants must be between 30 and 65 years of age.
• Participants must be able to provide sound written informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf.

Exclusion criteria

• Participants must not have prior hypersensitivity or adverse events to any of the components in the customized prescription.
• Participants must not be pregnant or breastfeeding women.
• Participants must not be managed outside the Medimix Specialty Pharmacy system with regard to their bioidentical hormone replacement therapy.
• Participants must not be using another bioidentical hormone at the time of enrollment.